Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 159,933 | 166,496 | 139,292 | 164,877 | 139,494 |
| Cost of Goods | 27,991 | 23,002 | 28,662 | 16,894 | 21,021 |
| Gross Profit | 131,942 | 143,494 | 110,630 | 147,983 | 118,473 |
| Operating Expenses | 303,823 | 251,384 | 254,231 | 271,155 | 250,481 |
| Operating Income | -170,890 | -107,888 | -142,939 | -122,278 | -131,987 |
| Interest Expense | 14,148 | 14,041 | 14,342 | 15,522 | 15,712 |
| Other Income | 5,498 | 7,925 | 7,511 | 4,396 | 14,486 |
| Pre-tax Income | -179,540 | -114,004 | -149,770 | -133,404 | -133,213 |
| Income Tax | 873 | 947 | 1,310 | -19 | 303 |
| Net Income Continuous | -180,413 | -114,951 | -151,080 | -133,385 | -133,516 |
| Net Income | $-180,413 | $-114,951 | $-151,080 | $-133,385 | $-133,516 |
| EPS Basic Total Ops | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 |
| EPS Basic Continuous Ops | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 |
| EPS Diluted Total Ops | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 |
| EPS Diluted Continuous Ops | -1.81 | -1.17 | -1.57 | -1.34 | -1.40 |
| EPS Diluted Before Non-Recurring Items | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 |
| EBITDA(a) | $-162,988 | $-100,316 | $-135,682 | $-116,005 | $-126,345 |